Our findings provide novel insights into the molecular basis of chemoresistance in CRC and highlight the CYP19A1/estrogen/complex I axis as a promising therapeutic target for overcoming drug resistance and improving patient outcomes. The gene discussed is CYP19A1; the disease is colorectal carcinoma.